Perspectives
"Hereditary AngioEdema (HAE) is a rare, severely debilitating genetic disease that has been diagnosed in approximately 10,000 people in the US and EU. Yet significant furor surrounds the recent developments in HAE treatment options. Why is there so much interest and increasing competition for a niche indication for which an approved product is unlikely to achieve more than $300-400m in worldwide peak sales? " ... Read more
22 Jul 2008 | From the latest Perspectives entry by Subita Srimal, Hereditary AngioEdema: Targeting Niche Indications Fetches A Premium
Research Library . Recent Updates
| 18 Aug 2008 | Biogen's Tysabri and Elan Company Update » |
|---|---|
| 14 Aug 2008 | Target Analysis Rpt - Syk inhibitors in Rheumatoid Arthritis RIGL » |
| 12 Aug 2008 | EXEL - Report on Strategic Direction » |
| 6 Aug 2008 | Therapeutic Market Report - Alzheimer's Disease » |
| 5 Aug 2008 | Cadence Re-Emerges » |
